Home Newsfeeds Precigen To Present Late-Breaking Abstract For Pivotal Phase 2 Study Data For PRGN-2012 AdenoVerse Immunotherapy For The Treatment Of Patients With Recurrent Respiratory Papillomatosis At The 2024 ASCO Annual Meeting

Precigen To Present Late-Breaking Abstract For Pivotal Phase 2 Study Data For PRGN-2012 AdenoVerse Immunotherapy For The Treatment Of Patients With Recurrent Respiratory Papillomatosis At The 2024 ASCO Annual Meeting

Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced clinical data from the pivotal Phase

byBenzinga Newsdesk

April 24, 2024

1 minute read

investors.precigen.com/events-presentations.

Independent Study Results In Japan Demonstrate 0% Breast Cancer Local Recurrence 5 Years Following Treatment With IceCure’s ProSense, Adding To Continued Data Published Globally

By Benzinga Newsdesk

May 7, 8:45 AM

Study published in the peer reviewed journal Breast CancerExcellent cosmetic outcomes, high degree of patient satisfaction, and improved quality of life post-cryoablationStrategic distribution partner

ICCM

Arcutis Gets FDA Nod For Plaque Psoriasis Candidate, Sees Commercial Launch In Mid-August

By Ragothaman Srinivasan

July 29, 4:36 PM

The U.S. Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ (NASDAQ: ARQT) New Drug Application (NDA) for ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis in patients 12 years of age or older.

ARQT